{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:25:04Z","timestamp":1792167904134,"version":"4.4.0"},"reference-count":197,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0 http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Alzheimer\u2019s disease is a common neurodegenerative disease characterized by progressive memory loss, cognitive decline, and behavioral changes. Blood-based biomarkers have recently gained significant attention due to their accessibility and cost-effectiveness. This review highlights the latest progress in multiple key areas of blood-based biomarkers for Alzheimer\u2019s disease. For early diagnosis, blood-based biomarkers such as amyloid-\u03b2 and phosphorylated tau can identify Alzheimer\u2019s disease even before clinical symptoms emerge. Dynamic changes in blood-based biomarkers, including p-tau217 and neurofilament light chain, reflect disease progression and correlate with cognitive decline, enabling continuous monitoring of Alzheimer\u2019s disease progression. Additionally, blood-based biomarkers such as p-tau181 and glial fibrillary acidic protein aid in differential diagnosis by distinguishing Alzheimer\u2019s disease from other dementias such as frontotemporal dementia. Blood-based biomarkers related to nerve repair have opened up new avenues for tracking nerve regeneration and therapeutic response, especially brain-derived neurotrophic factor. Furthermore, advanced detection technologies such as single-molecule array and immunoprecipitation-mass spectrometry have significantly improved the sensitivity and specificity of blood-based biomarkers, facilitating their clinical translation. In summary, blood-based biomarkers hold strong potential to improve early diagnosis, monitor progression, differential diagnosis, and evaluate therapies in Alzheimer\u2019s disease. This review provides a comprehensive and updated evaluation of the translational potential of blood-based biomarkers, emphasizing their practical utility in clinical settings and offering insights into future directions for large-scale application. This review emphasizes the need to prioritize the allocation of scientific resources, expedite the transition of blood-based biomarkers to clinical implementation, and ultimately achieve precise treatment of Alzheimer\u2019s disease using these biomarkers.<\/jats:p>","DOI":"10.4103\/nrr.nrr-d-25-00759","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:00:19Z","timestamp":1770008419000},"page":"4843-4853","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Blood-based biomarkers and early diagnosis of Alzheimer\u2019s disease"],"prefix":"10.4103","volume":"21","author":[{"given":"Zhikang","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Heze Municipal Hospital, Heze, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyong","family":"Wei","sequence":"additional","affiliation":[{"name":"Xiajin County People\u2019s Hospital, Dezhou, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9307-7009","authenticated-orcid":false,"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1228-5739","authenticated-orcid":false,"given":"Zhiming","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"},{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"100205","DOI":"10.1016\/j.tjpad.2025.100205","article-title":"Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer\u2019s disease","volume":"12","author":"Abbas","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/d41586-024-02535-x","article-title":"Blood tests could soon predict your risk of Alzheimer\u2019s","volume":"632","author":"Abbott","year":"2024","journal-title":"Nature"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","article-title":"GDNF, NGF and BDNF as therapeutic options for neurodegeneration","volume":"138","author":"Allen","year":"2013","journal-title":"Pharmacol Ther"},{"key":"R4-20260803","first-page":"e12451","article-title":"Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study","volume":"15","author":"Allu\u00e9","year":"2023","journal-title":"Alzheimers Dement"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","article-title":"Diagnostic performance of plasma pTau217, pTau181, A\u03b21\u201342 and A\u03b21\u201340 in the LUMIPULSE automated platform for the detection of Alzheimer disease","volume":"16","author":"Arranz","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R6-20260803","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11033-023-08959-4","article-title":"Neurotrophin growth factors and their receptors as promising blood biomarkers for Alzheimer\u2019s disease: a gene expression analysis study","volume":"51","author":"Asadi","year":"2024","journal-title":"Mol Biol Rep"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"R9-20260803","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/kjm2.12870","article-title":"Advances in blood biomarkers for Alzheimer disease (AD): a review","volume":"40","author":"Assfaw","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13195-021-00873-w","article-title":"Plasma amyloid-\u03b2 oligomerization assay as a pre-screening test for amyloid status","volume":"13","author":"BabapourMofrad","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","article-title":"Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"14","author":"Baldacci","year":"2017","journal-title":"Expert Rev Proteomics"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","article-title":"Frontotemporal dementia","volume":"386","author":"Bang","year":"2015","journal-title":"Lancet"},{"key":"R13-20260803","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"key":"R14-20260803","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","article-title":"Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From preclinical studies to the clinical trials","volume":"28","author":"Basheer","year":"2023","journal-title":"Mol Psychiatry"},{"key":"R15-20260803","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/alz.13687","article-title":"Fully automated measurement of plasma A\u03b242\/40 and p-tau181: analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer\u2019s disease continuum in two independent cohorts","volume":"20","author":"Bellomo","year":"2024","journal-title":"Alzheimers Dement"},{"key":"R16-20260803","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-023-02594-w","article-title":"Plasma biomarkers for prediction of Alzheimer\u2019s disease neuropathologic change","volume":"146","author":"Bermudez","year":"2023","journal-title":"Acta Neuropathol (Berl)"},{"key":"R17-20260803","doi-asserted-by":"crossref","first-page":"e14414","DOI":"10.1002\/alz.14414","article-title":"Biomarker treatment effects in two phase 3 trials of gantenerumab","volume":"21","author":"Bittner","year":"2025","journal-title":"Alzheimers Dement"},{"key":"R18-20260803","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.brs.2011.06.006","article-title":"Prolonged visual memory enhancement after direct current stimulation in Alzheimer\u2019s disease","volume":"5","author":"Boggio","year":"2012","journal-title":"Brain Stimul"},{"key":"R19-20260803","doi-asserted-by":"crossref","first-page":"100310","DOI":"10.1016\/j.tjpad.2025.100310","article-title":"Disclosure of Alzheimer\u2019s disease blood-based biomarker results in a primary care setting: opportunities and challenges","author":"Bolton","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"R20-20260803","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3233\/JAD-221010","article-title":"Cerebrospinal fluid sTREM-2, GFAP, and \u03b2-S100 in symptomatic sporadic Alzheimer\u2019s disease: microglial, astrocytic, and APOE contributions along the Alzheimer\u2019s disease continuum Bozzali M, ed","volume":"92","author":"Bonomi","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"R21-20260803","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3233\/JPD-240002","article-title":"Parkinson\u2019s disease and dementia with Lewy bodies: one and the same","volume":"14","author":"Borghammer","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"R22-20260803","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3390\/medicina61081462","article-title":"From better diagnostics to earlier treatment: the rapidly evolving Alzheimer\u2019s disease landscape","volume":"61","author":"Bougea","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"R23-20260803","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"R24-20260803","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"key":"R25-20260803","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13195-023-01296-5","article-title":"Performance of plasma A\u03b242\/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status","volume":"15","author":"Bun","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"R26-20260803","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","article-title":"Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts","volume":"14","author":"Cai","year":"2023","journal-title":"Nat Commun"},{"key":"R27-20260803","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12951-021-00864-x","article-title":"Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer\u2019s disease: from current to future challenges","volume":"19","author":"Cano","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"R28-20260803","doi-asserted-by":"crossref","first-page":"708","DOI":"10.14283\/jpad.2022.78","article-title":"Age, sex, hypertension and HDL-C alter serum BACE1 activity in cognitively normal subjects: implications for Alzheimer\u2019s disease","volume":"9","author":"Cervellati","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"R29-20260803","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1002\/alz.12879","article-title":"Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer\u2019s disease: associations with A\u03b2-PET, neurodegeneration, and cognition","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement"},{"key":"R30-20260803","doi-asserted-by":"crossref","first-page":"17919","DOI":"10.1038\/s41598-022-22647-6","article-title":"Relevance of plasma biomarkers to pathologies in Alzheimer\u2019s disease, Parkinson\u2019s disease and frontotemporal dementia","volume":"12","author":"Chiu","year":"2022","journal-title":"Sci Rep"},{"key":"R31-20260803","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy","volume":"93","author":"Chouliaras","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R32-20260803","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"R33-20260803","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/diagnostics14070704","article-title":"Neuropathology, neuroimaging, and fluid biomarkers in Alzheimer\u2019s disease","volume":"14","author":"Colvee-Martin","year":"2024","journal-title":"Diagnostics"},{"key":"R34-20260803","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/alz.12612","article-title":"Potential role of chitinase-3-like protein 1 (CHI3L1\/YKL-40) in neurodegeneration and Alzheimer\u2019s disease","volume":"19","author":"Connolly","year":"2023","journal-title":"Alzheimers Dement"},{"key":"R35-20260803","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"R36-20260803","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.3390\/ijms25094594","article-title":"Assessment of the correlation and diagnostic accuracy between cerebrospinal fluid and plasma Alzheimer\u2019s disease biomarkers: a comparison of the lumipulse and simoa platforms","volume":"25","author":"Dakterzada","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R37-20260803","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41398-024-03072-x","article-title":"Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: findings from the Co-STAR study","volume":"14","author":"Daniilidou","year":"2024","journal-title":"Transl Psychiatry"},{"key":"R38-20260803","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13195-024-01459-y","article-title":"Alzheimer\u2019s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline","volume":"16","author":"Dark","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R39-20260803","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbi.2023.03.001","article-title":"Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies","volume":"110","author":"De Bastiani","year":"2023","journal-title":"Brain Behav Immun"},{"key":"R40-20260803","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/brain\/awad330","article-title":"Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes","volume":"147","author":"De Meyer","year":"2024","journal-title":"Brain"},{"key":"R41-20260803","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-021-00234-5","article-title":"Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"10","author":"Ding","year":"2021","journal-title":"Transl Neurodegener"},{"key":"R42-20260803","doi-asserted-by":"crossref","first-page":"afae005","DOI":"10.1093\/ageing\/afae005","article-title":"New horizons in the diagnosis and management of Alzheimer\u2019s disease in older adults","volume":"53","author":"Dolphin","year":"2024","journal-title":"Age Ageing"},{"key":"R43-20260803","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"R44-20260803","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3233\/JAD-230932","article-title":"Plasma amyloid-\u03b2, total Tau, and neurofilament light chain across the Alzheimer\u2019s disease clinical spectrum: a population-based study","volume":"96","author":"Dong","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"R45-20260803","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3390\/jcm12144689","article-title":"Potential utility of cerebrospinal fluid glycoprotein nonmetastatic melanoma protein b as a neuroinflammatory diagnostic biomarker in mild cognitive impairment and Alzheimer\u2019s disease","volume":"12","author":"Doroszkiewicz","year":"2023","journal-title":"J Clin Med"},{"key":"R46-20260803","doi-asserted-by":"crossref","first-page":"133","DOI":"10.20517\/evcna.2023.13","article-title":"Synaptic proteins in neuron-derived extracellular vesicles as biomarkers for Alzheimer\u2019s disease: novel methodology and clinical proof of concept","volume":"4","author":"Eitan","year":"2023","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"key":"R47-20260803","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(21)00139-3","article-title":"Comparison of CSF biomarkers in down syndrome and autosomal dominant Alzheimer\u2019s disease: a cross-sectional study","volume":"20","author":"Fagan","year":"2021","journal-title":"Lancet Neurol"},{"key":"R48-20260803","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3233\/JAD-215423","article-title":"The efficacy and safety of Alzheimer\u2019s disease therapies: an updated umbrella review","volume":"85","author":"Fan","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"R49-20260803","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1080\/10408347.2022.2132812","article-title":"Advancement in analytical techniques for determining the activity of \u03b2-site amyloid precursor protein cleaving enzyme 1","volume":"54","author":"Fan","year":"2024","journal-title":"Crit Rev Anal Chem"},{"key":"R50-20260803","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31083\/j.jin2204085","article-title":"Neurofilament light chain as a potential biomarker in plasma for Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and a meta-analysis","volume":"22","author":"Fan","year":"2023","journal-title":"J Integr Neurosci"},{"key":"R51-20260803","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.scib.2023.07.009","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: a multicenter-based cross-sectional and longitudinal study in China","volume":"68","author":"Feng","year":"2023","journal-title":"Sci Bull"},{"key":"R52-20260803","doi-asserted-by":"crossref","first-page":"e12545","DOI":"10.1002\/dad2.12545","article-title":"Performance of the lumipulse plasma A\u03b242\/40 and pTau181 immunoassays in the detection of amyloid pathology","volume":"16","author":"Figdore","year":"2024","journal-title":"Alzheimers Dement (Amst)"},{"key":"R53-20260803","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41582-025-01090-x","article-title":"Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important?","volume":"21","author":"Fu","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"R54-20260803","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/s41593-024-01763-8","article-title":"Synergistic association of A\u03b2 and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults","volume":"27","author":"Gallego-Rudolf","year":"2024","journal-title":"Nat Neurosci"},{"key":"R55-20260803","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3892\/etm.2023.12143","article-title":"Enhancement of neural regeneration as a therapeutic strategy for Alzheimer\u2019s disease (Review)","volume":"26","author":"Gao","year":"2023","journal-title":"Exp Ther Med"},{"key":"R56-20260803","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41593-022-01041-5","article-title":"Single-neuron projectome of mouse prefrontal cortex","volume":"25","author":"Gao","year":"2022","journal-title":"Nat Neurosci"},{"key":"R57-20260803","doi-asserted-by":"crossref","first-page":"120805","DOI":"10.1016\/j.jns.2023.120805","article-title":"Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer\u2019s disease pathology in subjective cognitive decline and mild cognitive impairment","volume":"453","author":"Giacomucci","year":"2023","journal-title":"J Neurol Sci"},{"key":"R58-20260803","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","article-title":"Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications","volume":"18","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Mol Neurodegener"},{"key":"R59-20260803","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer\u2019s disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"R60-20260803","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.biopsych.2020.06.029","article-title":"Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer\u2019s disease pathophysiology","volume":"89","author":"Guo","year":"2021","journal-title":"Biol Psychiatry"},{"key":"R61-20260803","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13195-023-01174-0","article-title":"The dynamics of plasma biomarkers across the Alzheimer\u2019s continuum","volume":"15","author":"Guo","year":"2023","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"R62-20260803","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-Secretase BACE1 in Alzheimer\u2019s disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol Psychiatry"},{"key":"R63-20260803","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX (N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"R64-20260803","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"R65-20260803","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"R66-20260803","first-page":"326","article-title":"Blood based biomarker for optimization of early and differential diagnosis of Alzheimer\u2019s dementia","volume":"90","author":"Hansen","year":"2022","journal-title":"Fortschr Neurol Psychiatr"},{"key":"R67-20260803","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"key":"R68-20260803","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"key":"R69-20260803","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","article-title":"Effects of oral ALZ-801\/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer\u2019s disease","volume":"84","author":"Hey","year":"2024","journal-title":"Drugs"},{"key":"R70-20260803","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1038\/s41467-024-52937-8","article-title":"Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer\u2019s disease","volume":"15","author":"Hofmann","year":"2024","journal-title":"Nat Commun"},{"key":"R71-20260803","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","article-title":"Lecanemab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"R72-20260803","doi-asserted-by":"crossref","first-page":"e228392","DOI":"10.1001\/jamanetworkopen.2022.8392","article-title":"Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment","volume":"5","author":"Hu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R73-20260803","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41380-024-02709-z","article-title":"Alzheimer\u2019s disease biomarkers and their current use in clinical research and practice","volume":"30","author":"Hunter","year":"2024","journal-title":"Mol Psychiatry"},{"key":"R74-20260803","doi-asserted-by":"crossref","first-page":"e0151081","DOI":"10.1371\/journal.pone.0151081","article-title":"Periodontitis and cognitive decline in Alzheimer\u2019s disease","volume":"11","author":"Ide","year":"2016","journal-title":"PLoS One"},{"key":"R75-20260803","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/CIRCRESAHA.122.321078","article-title":"Endothelial BACE1: bridging the gap between hypertension and Alzheimer\u2019s disease","volume":"130","author":"Ihara","year":"2022","journal-title":"Circ Res"},{"key":"R76-20260803","doi-asserted-by":"crossref","first-page":"1375302","DOI":"10.3389\/fendo.2024.1375302","article-title":"Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia","volume":"15","author":"Ingannato","year":"2024","journal-title":"Front Endocrinol"},{"key":"R77-20260803","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s40001-024-01915-3","article-title":"Alzheimer\u2019s disease and drug delivery across the blood-brain barrier: approaches and challenges","volume":"29","author":"Iqbal","year":"2024","journal-title":"Eur J Med Res"},{"key":"R78-20260803","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"R79-20260803","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/NRR.NRR-D-24-01019","article-title":"Neuronal plasticity and its role in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"21","author":"Jahan","year":"2026","journal-title":"Neural Regen Res"},{"key":"R80-20260803","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"key":"R81-20260803","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"R82-20260803","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","article-title":"Plasma phosphorylated Tau 217 and A\u03b242\/40 to predict early brain A\u03b2 accumulation in people without cognitive impairment","volume":"81","author":"Janelidze","year":"2024","journal-title":"JAMA Neurol"},{"key":"R83-20260803","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/biomedicines12040786","article-title":"Evaluating p-tau217 and p-tau231 as biomarkers for early diagnosis and differentiation of Alzheimer\u2019s disease: a narrative review","volume":"12","author":"Jarek","year":"2024","journal-title":"Biomedicines"},{"key":"R84-20260803","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJMoa2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer\u2019s disease","volume":"390","author":"Jia","year":"2024","journal-title":"N Engl J Med"},{"key":"R85-20260803","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/brain\/awac399","article-title":"Plasma biomarker profiles in autosomal dominant Alzheimer\u2019s disease","volume":"146","author":"Johansson","year":"2023","journal-title":"Brain"},{"key":"R86-20260803","first-page":"543","article-title":"Biomarkers in Alzheimer\u2019s disease: role in early and differential diagnosis and recognition of atypical variants","volume":"17","author":"Ju","year":"2022","journal-title":"Neural Regen Res"},{"key":"R87-20260803","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40265-024-02087-4","article-title":"Donanemab: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"R88-20260803","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"Kang","year":"1987","journal-title":"Nature"},{"key":"R89-20260803","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"R90-20260803","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl Neurodegener"},{"key":"R91-20260803","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13195-022-01104-6","article-title":"Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status","volume":"14","author":"Kim","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"R92-20260803","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/cells12091309","article-title":"GFAP as a potential biomarker for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2023","journal-title":"Cells"},{"key":"R93-20260803","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40035-022-00296-z","article-title":"Advances in the development of new biomarkers for Alzheimer\u2019s disease","volume":"11","author":"Klyucherev","year":"2022","journal-title":"Transl Neurodegener"},{"key":"R94-20260803","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neurobiolaging.2024.05.016","article-title":"Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer\u2019s disease","volume":"141","author":"Knudtzon","year":"2024","journal-title":"Neurobiol Aging"},{"key":"R95-20260803","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13195-024-01477-w","article-title":"Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE \u03b54-enriched cognitively unimpaired elderly","volume":"16","author":"Koivum\u00e4ki","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R96-20260803","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2174\/0113892010308600240709052539","article-title":"Immunotherapies: a treasure trove of Alzheimer\u2019s disease","volume":"26","author":"Kolay","year":"2025","journal-title":"Curr Pharm Biotechnol"},{"key":"R97-20260803","doi-asserted-by":"crossref","first-page":"102599","DOI":"10.1016\/j.arr.2024.102599","article-title":"An overview of the genes and biomarkers in Alzheimer\u2019s disease","volume":"104","author":"Krishnamurthy","year":"2025","journal-title":"Ageing Res Rev"},{"key":"R98-20260803","doi-asserted-by":"crossref","first-page":"eaax3519","DOI":"10.1126\/scitranslmed.aax3519","article-title":"Chi3l1\/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer\u2019s disease pathogenesis","volume":"12","author":"Lananna","year":"2020","journal-title":"Sci Transl Med"},{"key":"R99-20260803","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13024-024-00741-9","article-title":"Tau protein profiling in tauopathies: a human brain study","volume":"19","author":"Lantero-Rodriguez","year":"2024","journal-title":"Mol Neurodegener"},{"key":"R100-20260803","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13195-021-00953-x","article-title":"Serum neurofilament light chain level as a predictor of cognitive stage transition","volume":"14","author":"Lee","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"R101-20260803","doi-asserted-by":"crossref","first-page":"17361","DOI":"10.3390\/ijms242417361","article-title":"Blood neurofilament levels predict cognitive decline across the Alzheimer\u2019s disease continuum","volume":"24","author":"Lehmann","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R102-20260803","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00259-021-05258-7","article-title":"2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R103-20260803","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neuron.2009.05.012","article-title":"Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake","volume":"62","author":"Li","year":"2009","journal-title":"Neuron"},{"key":"R104-20260803","first-page":"e688","article-title":"Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"key":"R105-20260803","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40035-023-00365-x","article-title":"Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints","volume":"12","author":"Lu","year":"2023","journal-title":"Transl Neurodegener"},{"key":"R106-20260803","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jama.2024.6619","article-title":"Changes in Alzheimer disease blood biomarkers and associations with incident all-cause dementia","volume":"332","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"R107-20260803","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13195-023-01319-1","article-title":"Accuracy of plasma A\u03b240, A\u03b242, and p-tau181 to detect CSF Alzheimer\u2019s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform","volume":"15","author":"Mart\u00ednez-Dubarbie","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"R108-20260803","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer\u2019s disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R109-20260803","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"R110-20260803","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"R111-20260803","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"R112-20260803","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40035-024-00450-9","article-title":"Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson\u2019s and Alzheimer\u2019s disease","volume":"13","author":"McDowall","year":"2024","journal-title":"Transl Neurodegener"},{"key":"R113-20260803","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-024-01478-9","article-title":"Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients","volume":"16","author":"Mendes","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R114-20260803","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13195-019-0535-7","article-title":"Association between increased levels of amyloid-\u03b2 oligomers in plasma and episodic memory loss in Alzheimer\u2019s disease","volume":"11","author":"Meng","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"R115-20260803","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ana.26308","article-title":"Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults","volume":"91","author":"Meyer","year":"2022","journal-title":"Ann Neurol"},{"key":"R116-20260803","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"key":"R117-20260803","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2023.12.001","article-title":"An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer\u2019s brains","volume":"57","author":"Millet","year":"2024","journal-title":"Immunity"},{"key":"R118-20260803","doi-asserted-by":"crossref","first-page":"115522","DOI":"10.1016\/j.bcp.2023.115522","article-title":"Alzheimer\u2019s disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs","volume":"211","author":"Monteiro","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"R119-20260803","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-023-02660-3","article-title":"Optimal blood tau species for the detection of Alzheimer\u2019s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study","volume":"147","author":"Montoliu-Gaya","year":"2023","journal-title":"Acta Neuropathol"},{"key":"R120-20260803","doi-asserted-by":"crossref","first-page":"104547","DOI":"10.1016\/j.ebiom.2023.104547","article-title":"Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with down syndrome: a longitudinal cohort study","volume":"90","author":"Montoliu-Gaya","year":"2023","journal-title":"eBioMedicine"},{"key":"R121-20260803","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1038\/s41598-023-32515-6","article-title":"A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress","volume":"13","author":"Morat\u00f3","year":"2023","journal-title":"Sci Rep"},{"key":"R122-20260803","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00406-023-01751-2","article-title":"Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer\u2019s disease","volume":"275","author":"Morgado","year":"2024","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R123-20260803","first-page":"e70102","article-title":"Therapeutic time window of disease-modifying therapy for early Alzheimer\u2019s disease","volume":"11","author":"Nakashima","year":"2025","journal-title":"Alzheimers Dement"},{"key":"R124-20260803","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/svn-2025-004048","article-title":"Updates on vascular dementia","volume":"10","author":"Ng","year":"2025","journal-title":"Stroke Vasc Neurol"},{"key":"R125-20260803","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3233\/JAD-215542","article-title":"Increased serum beta-secretase 1 activity is an early marker of Alzheimer\u2019s disease","volume":"87","author":"Nicsanu","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"R126-20260803","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41512-024-00167-3","article-title":"Blood levels of glial fibrillary acidic protein for predicting clinical progression to Alzheimer\u2019s disease in adults without dementia: a systematic review and meta-analysis protocol","volume":"8","author":"Nihashi","year":"2024","journal-title":"Diagn Progn Res"},{"key":"R127-20260803","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13195-024-01469-w","article-title":"Combining plasma A\u03b2 and p-tau217 improves detection of brain amyloid in non-demented elderly","volume":"16","author":"Niimi","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R128-20260803","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00401-014-1371-2","article-title":"Tau aggregation and its interplay with amyloid-\u03b2","volume":"129","author":"Nisbet","year":"2015","journal-title":"Acta Neuropathol (Berl)"},{"key":"R129-20260803","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/jnnp-2022-329663","article-title":"Plasma GFAP in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study","volume":"94","author":"O\u2019Connor","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R130-20260803","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3233\/JAD-180325","article-title":"Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"R131-20260803","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2021-328547","article-title":"Serum GFAP differentiates Alzheimer\u2019s disease from frontotemporal dementia and predicts MCI-to-dementia conversion","author":"Oeckl","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R132-20260803","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"R133-20260803","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40035-023-00371-z","article-title":"The potential impact of clinical factors on blood-based biomarkers for Alzheimer\u2019s disease","volume":"12","author":"Pan","year":"2023","journal-title":"Transl Neurodegener"},{"key":"R134-20260803","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/biomedicines10010169","article-title":"Diagnostic blood biomarkers in Alzheimer\u2019s disease","volume":"10","author":"Park","year":"2022","journal-title":"Biomedicines"},{"key":"R135-20260803","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-022-01143-z","article-title":"Clinical performance of an antibody-free assay for plasma A\u03b242\/A\u03b240 to detect early alterations of Alzheimer\u2019s disease in individuals with subjective cognitive decline","volume":"15","author":"Pascual-Lucas","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"R136-20260803","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1021\/acssensors.5c02453","article-title":"Electrochemical biosensors combined with nanomaterial signal amplification for the detection of Alzheimer\u2019s disease biomarkers in blood","volume":"10","author":"Peng","year":"2025","journal-title":"ACS Sens"},{"key":"R137-20260803","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/brain\/awab163","article-title":"Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"R138-20260803","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3233\/JAD-210342","article-title":"Plasma neurofilament light chain predicts cognitive progression in prodromal and clinical dementia with Lewy bodies","volume":"82","author":"Pilotto","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"R139-20260803","article-title":"Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison","author":"Pilotto","year":"2024","journal-title":"medRxiv [Preprint]"},{"key":"R140-20260803","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/ijms24010778","article-title":"ApoE4 and Alzheimer\u2019s disease pathogenesis-mitochondrial deregulation and targeted therapeutic strategies","volume":"24","author":"Pires","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R141-20260803","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"R142-20260803","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/CIA.S312473","article-title":"Plasma amyloid-\u03b2 oligomerization tendency predicts amyloid PET positivity","volume":"16","author":"Pyun","year":"2021","journal-title":"Clin Interv Aging"},{"key":"R143-20260803","doi-asserted-by":"crossref","first-page":"e210211","DOI":"10.1212\/WNL.0000000000210211","article-title":"Comparison of plasma p-tau217 and [18F]FDG-PET for identifying Alzheimer disease in people with early-onset or atypical dementia","volume":"104","author":"Quispialaya","year":"2025","journal-title":"Neurology"},{"key":"R144-20260803","article-title":"Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression","author":"Rabl","year":"2024","journal-title":"Res Sq"},{"key":"R145-20260803","doi-asserted-by":"crossref","first-page":"e70293","DOI":"10.1002\/alz.70293","article-title":"TRAILBLAZER\u2010ALZ 4: a phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer\u2019s disease","volume":"21","author":"Salloway","year":"2025","journal-title":"Alzheimers Dement"},{"key":"R146-20260803","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.3390\/ijms25158354","article-title":"Serum beta-secretase 1 activity is a potential marker for the differential diagnosis between Alzheimer\u2019s disease and frontotemporal dementia: apilot study","volume":"25","author":"Saraceno","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R147-20260803","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology","volume":"20","author":"Schindler","year":"2024","journal-title":"Alzheimers Dement"},{"key":"R148-20260803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12035-022-02891-7","article-title":"Validation of plasma and CSF neurofilament light chain as an early marker for sporadic Creutzfeldt-Jakob disease","volume":"59","author":"Schmitz","year":"2022","journal-title":"Mol Neurobiol"},{"key":"R149-20260803","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1002\/mds.28738","article-title":"Systematic assessment of 10 biomarker candidates focusing on \u03b1-synuclein-related disorders","volume":"36","author":"Schulz","year":"2021","journal-title":"Mov Disord"},{"key":"R150-20260803","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1007\/s11064-024-04244-3","article-title":"Emerging trends: neurofilament biomarkers in precision neurology","volume":"49","author":"Sharma","year":"2024","journal-title":"Neurochem Res"},{"key":"R151-20260803","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol"},{"key":"R152-20260803","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","article-title":"Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression","volume":"69","author":"Shen","year":"2023","journal-title":"Clin Chem"},{"key":"R153-20260803","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/ene.15762","article-title":"Blood biomarkers in mild cognitive impairment patients: relationship between analytes and progression to Alzheimer disease dementia","volume":"30","author":"Silva\u2010Sp\u00ednola","year":"2023","journal-title":"Eur J Neurol"},{"key":"R154-20260803","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13195-024-01397-9","article-title":"Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer\u2019s disease pathology","volume":"16","author":"Silva-Sp\u00ednola","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R155-20260803","doi-asserted-by":"crossref","first-page":"e12512","DOI":"10.1002\/dad2.12512","article-title":"Neurofilament light chain levels in serum among a large mixed memory clinic cohort: confounders and diagnostic usefulness","volume":"15","author":"Simonsen","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"key":"R156-20260803","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease","volume":"17","author":"Simr\u00e9n","year":"2021","journal-title":"Alzheimers Dement"},{"key":"R157-20260803","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"R158-20260803","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","article-title":"Plasma biomarkers for Alzheimer\u2019s disease in relation to neuropathology and cognitive change","volume":"143","author":"Smirnov","year":"2022","journal-title":"Acta Neuropathol (Berl)"},{"key":"R159-20260803","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - Binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"R160-20260803","doi-asserted-by":"crossref","first-page":"fcaf094","DOI":"10.1093\/braincomms\/fcaf094","article-title":"Plasma biomarkers for diagnosis and differentiation and their cognitive correlations in patients with Alzheimer\u2019s disease","volume":"7","author":"Sun","year":"2025","journal-title":"Brain Commun"},{"key":"R161-20260803","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","article-title":"Alzheimer\u2019s disease: epidemiology and clinical progression","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"R162-20260803","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s40120-023-00504-6","article-title":"A systematic review of clinical practice guidelines for Alzheimer\u2019s disease and strategies for future advancements","volume":"12","author":"Tahami Monfared","year":"2023","journal-title":"Neurol Ther"},{"key":"R163-20260803","first-page":"e70155","article-title":"Sex differences in treatment effects of lecanemab and donanemab: a Bayesian reanalysis of CLARITY-AD and TRAILBLAZER-ALZ2","volume":"11","author":"Teipel","year":"2025","journal-title":"Alzheimers Dement"},{"key":"R164-20260803","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2022.03.018","article-title":"P-tau217 in Alzheimer\u2019s disease","volume":"531","author":"Telser","year":"2022","journal-title":"Clin Chim Acta"},{"key":"R165-20260803","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"R166-20260803","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00401-024-02722-0","article-title":"Regulated cell death and its role in Alzheimer\u2019s disease and amyotrophic lateral sclerosis","volume":"147","author":"Thal","year":"2024","journal-title":"Acta Neuropathol"},{"key":"R167-20260803","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","article-title":"Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability","volume":"4","author":"Therriault","year":"2024","journal-title":"Nat Aging"},{"key":"R168-20260803","doi-asserted-by":"crossref","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","article-title":"Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology","volume":"102","author":"Therriault","year":"2024","journal-title":"EBioMedicine"},{"key":"R169-20260803","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1474-4422(25)00227-3","article-title":"Blood phosphorylated tau for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"24","author":"Therriault","year":"2025","journal-title":"Lancet Neurol"},{"key":"R170-20260803","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"key":"R171-20260803","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/acn3.615","article-title":"Pre-amyloid stage of Alzheimer\u2019s disease in cognitively normal individuals","volume":"5","author":"Tijms","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"R172-20260803","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"R173-20260803","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.3390\/ijms22126355","article-title":"Neurotoxic soluble amyloid oligomers drive Alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression","volume":"22","author":"Tolar","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R174-20260803","doi-asserted-by":"crossref","first-page":"e14442","DOI":"10.1002\/alz.14442","article-title":"Plasma A\u03b242\/A\u03b240 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer\u2019s disease spectrum","volume":"21","author":"Trelle","year":"2025","journal-title":"Alzheimers Dement"},{"key":"R175-20260803","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/alz.13686","article-title":"Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer\u2019s disease and related dementias","volume":"20","author":"Tsoy","year":"2024","journal-title":"Alzheimers Dement"},{"key":"R176-20260803","doi-asserted-by":"crossref","first-page":"101622","DOI":"10.1016\/j.arr.2022.101622","article-title":"Glial cells in Alzheimer\u2019s disease: from neuropathological changes to therapeutic implications","volume":"78","author":"Uddin","year":"2022","journal-title":"Ageing Res Rev"},{"key":"R177-20260803","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"R178-20260803","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol (Berl)"},{"key":"R179-20260803","doi-asserted-by":"crossref","first-page":"1599048","DOI":"10.3389\/fphar.2025.1599048","article-title":"Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab\/donanemab) in the treatment of early Alzheimer\u2019s disease","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"R180-20260803","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13195-024-01400-3","article-title":"Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer\u2019s disease spectrum","volume":"16","author":"Wang","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R181-20260803","doi-asserted-by":"crossref","first-page":"122282","DOI":"10.1016\/j.lfs.2023.122282","article-title":"TrkB\/BDNF signaling pathway and its small molecular agonists in CNS injury","volume":"336","author":"Wang","year":"2024","journal-title":"Life Sci"},{"key":"R182-20260803","doi-asserted-by":"crossref","first-page":"e095507","DOI":"10.1002\/alz.095507","article-title":"Lecanemabslows amyloid\u2010induced tau pathology as supported by CSF MTBR\u2010tau243 in clarity AD","volume":"20","author":"Wildsmith","year":"2024","journal-title":"Alzheimers Dement"},{"key":"R183-20260803","doi-asserted-by":"crossref","first-page":"106356","DOI":"10.1016\/j.nbd.2023.106356","article-title":"Trajectories of CSF and plasma biomarkers across Alzheimer\u2019s disease continuum: disease staging by NF-L, p-tau181, and GFAP","volume":"189","author":"Wojda\u0142a","year":"2023","journal-title":"Neurobiol Dis"},{"key":"R184-20260803","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00259-020-05118-w","article-title":"Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase biomarker development framework","volume":"48","author":"Wolters","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R185-20260803","doi-asserted-by":"crossref","first-page":"13771","DOI":"10.3390\/ijms241813771","article-title":"Plasma neurofilament light chains as blood-based biomarkers for early diagnosis of canine cognitive dysfunction syndrome","volume":"24","author":"Wu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R186-20260803","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu","year":"2023","journal-title":"Eur J Med Res"},{"key":"R187-20260803","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3233\/JAD-220673","article-title":"A review of application of A\u03b242\/40 ratio in diagnosis and prognosis of Alzheimer\u2019s disease","volume":"90","author":"Xu","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"R188-20260803","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1002\/alz.13318","article-title":"Longitudinal blood biomarker trajectories in preclinical Alzheimer\u2019s disease","volume":"19","author":"Yakoub","year":"2023","journal-title":"Alzheimers Dement"},{"key":"R189-20260803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","article-title":"Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults","volume":"146","author":"Yu","year":"2023","journal-title":"Acta Neuropathol (Berl)"},{"key":"R190-20260803","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4103\/NRR.NRR-D-24-00695","article-title":"Insights into the transcriptomic heterogeneity of brain endothelial cells in normal aging and Alzheimer\u2019s disease","volume":"21","author":"Yue","year":"2026","journal-title":"Neural Regen Res"},{"key":"R191-20260803","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13024-024-00753-5","article-title":"Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease","volume":"19","author":"Zeng","year":"2024","journal-title":"Mol Neurodegener"},{"key":"R192-20260803","doi-asserted-by":"crossref","first-page":"e14535","DOI":"10.1002\/alz.14535","article-title":"Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort","volume":"21","author":"Zeng","year":"2025","journal-title":"Alzheimers Dement"},{"key":"R193-20260803","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R194-20260803","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40035-024-00429-6","article-title":"Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl Neurodegener"},{"key":"R195-20260803","doi-asserted-by":"crossref","first-page":"102595","DOI":"10.1016\/j.arr.2024.102595","article-title":"Disease-modifying therapies for Alzheimer\u2019s disease: clinical trial progress and opportunity","volume":"103","author":"Zhang","year":"2025","journal-title":"Ageing Res Rev"},{"key":"R196-20260803","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/alz.12697","article-title":"Comparative analytical performance of multiple plasma A\u03b242 and A\u03b240 assays and their ability to predict positron emission tomography amyloid positivity","volume":"19","author":"Zicha","year":"2023","journal-title":"Alzheimers Dement"},{"key":"R197-20260803","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/NRR.NRR-D-25-00759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:32Z","timestamp":1786735712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/NRR.NRR-D-25-00759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":197,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/nrr.nrr-d-25-00759","relation":{},"ISSN":["1673-5374","1876-7958"],"issn-type":[{"value":"1673-5374","type":"print"},{"value":"1876-7958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"2025-05-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}